Bovine mastitis market size in 2026 is estimated at USD 1.76 billion, growing from 2025 value of USD 1.68 billion with 2031 projections showing USD 2.24 billion, growing at 4.88% CAGR over 2026-2031. This report is Segmented by Disease Type (Clinical Mastitis and Sub-Clinical Mastitis), Product (Antibiotics and More), Route of Administration (Intra-Mammary and Systemic), Therapy (Lactating Period and Dry Period), by End-User (Hospitals & Veterinary Clinics and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Subclinical infections trail in market value yet contribute 10%-20% latent yield loss, prompting investment in somatic-cell count trackers and AI pattern recognition. Smartphones now deliver 2-minute cell-count reads, nudging farms toward proactive cures that could soon narrow the revenue gap with clinical cases. As technology shrinks diagnostic costs, the subclinical sub-segment may accelerate faster than headline projections, adding depth to the bovine mastitis market.
Antibiotics accounted for 76.62% of the bovine mastitis market share in 2025 and are on track to grow at a good pace through 2031. Their dominance stems from fast, reliable cures in acute clinical cases, which protect both cow welfare and farm income. Regulators are tightening oversight; however, the European Union now restricts prophylactic use and scrutinizes critical drug classes, prompting more selective prescribing.
Vaccines are the quickest-rising category, advancing at a 5.62% CAGR, as prevention proves cheaper than treatment and supports industry efforts to curb antibiotic reliance. Zoetis’ Protivity for Mycoplasma bovis and other multi-pathogen projects show the pivot toward immunological control.
Europe follows a 4.92% CAGR backed by some of the world’s strictest antimicrobial policies. Regulation 2019/6 pushes selective dry-cow therapy and caps prophylactic use, intensifying demand for sensor-driven treatment decisions and alternative biologics. Nordic producers showcase low somatic-cell averages, proving preventive systems can maintain output while shrinking antibiotic loads.
Asia-Pacific is the fastest propeller with a 5.86% CAGR thanks to surging dairy consumption in China, India, and Southeast Asia. Larger herd sizes, international joint ventures, and Western farming models necessitate structured mastitis control. Investments in milk-analysis labs and vet services unlock pent-up demand for culture kits, vaccines, and AI platforms, enlarging regional share of the bovine mastitis market. Latin America and the Middle East & Africa trail at slightly lower yet robust CAGRs of 5.72% and 5.31% respectively as integrated farm projects scale up in Brazil and the Gulf states.
Global Bovine Mastitis Market Trends and Insights
Rising Incidence and Cost Burden
Mastitis affects one in four U.S. dairy cows each year, with every clinical case costing from USD 128 to USD 444 in lost milk, treatment, and culling expenses. Subclinical infections silently depress yield by 10% to 20% per cow, prompting European herds to adopt routine somatic-cell screening to avoid milk-quality penalties. The mounting financial toll steers producer budgets toward predictive analytics, vaccination programs, and selective therapy, which all underpin sustained demand in the bovine mastitis market.Growth in Veterinary Spending and Herd-Management Automation
Large farms are allocating bigger capital outlays to automated milking systems, inline sensors, and professional veterinary services. DeLaval and John Deere’s Milk Sustainability Center illustrates how cloud-based dashboards now merge feed, fertility, and udder-health data to boost profitability. Asia-Pacific herds are scaling rapidly, replicating Western automation models and lifting regional sales of diagnostics, vaccines, and decision-support software that keep the bovine mastitis market expanding at the fastest clip worldwide.Escalating Antimicrobial Resistance (AMR)
EU Regulation 2019/6 has banned prophylactic use and tightened metaphylactic approvals, forcing practitioners to blend systemic and intramammary drugs with NSAIDs to manage resistant strains. MRSA outbreaks in cattle shrink cure rates and elevate costs, dampening short-term growth until vaccines and phage solutions mature.Other drivers and restraints analyzed in the detailed report include:
- Technological Advances in On-Farm Diagnostics and Sensors
- Adoption of Short-Withdrawal Intramammary Antibiotics
- Low Farmer Adherence in Emerging Markets
Segment Analysis
Clinical mastitis held 58.02% of the bovine mastitis market size in 2025 and is expanding at 5.18% CAGR on the back of visible symptoms that demand immediate treatment to avoid milk loss and animal welfare penalties. Rapid therapy translates to higher spending per case, sustaining revenue streams for antibiotics and NSAIDs. The economic sting of each clinical outbreak keeps producers alert to early warning sensors that flag udder swelling or milk discoloration.Subclinical infections trail in market value yet contribute 10%-20% latent yield loss, prompting investment in somatic-cell count trackers and AI pattern recognition. Smartphones now deliver 2-minute cell-count reads, nudging farms toward proactive cures that could soon narrow the revenue gap with clinical cases. As technology shrinks diagnostic costs, the subclinical sub-segment may accelerate faster than headline projections, adding depth to the bovine mastitis market.
Antibiotics accounted for 76.62% of the bovine mastitis market share in 2025 and are on track to grow at a good pace through 2031. Their dominance stems from fast, reliable cures in acute clinical cases, which protect both cow welfare and farm income. Regulators are tightening oversight; however, the European Union now restricts prophylactic use and scrutinizes critical drug classes, prompting more selective prescribing.
Vaccines are the quickest-rising category, advancing at a 5.62% CAGR, as prevention proves cheaper than treatment and supports industry efforts to curb antibiotic reliance. Zoetis’ Protivity for Mycoplasma bovis and other multi-pathogen projects show the pivot toward immunological control.
Complete Report Scope:
- By Disease Type
- Clinical Mastitis
- Sub-clinical Mastitis
- By Product
- Antibiotics
- Vaccines
- NSAIDs & Pain-killers
- Others
- By Route of Administration
- Intramammary
- Systemic
- By Therapy
- Lactating Period
- Dry Period
- By End-User
- Hospitals & Veterinary Clinics
- Dairy Farms & Cooperatives
- Other End-Users
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America generated 33.12% of bovine mastitis market revenue in 2025 and will climb at 4.65% CAGR through 2031. Investment exceeding USD 8 billion in new U.S. processing capacity boosts milk-quality demands, motivating farms to adopt selective therapy and inline diagnostics. The FDA’s evolving antibacterial guidance shapes label claims and withdrawal times, rewarding firms that navigate compliance swiftly.Europe follows a 4.92% CAGR backed by some of the world’s strictest antimicrobial policies. Regulation 2019/6 pushes selective dry-cow therapy and caps prophylactic use, intensifying demand for sensor-driven treatment decisions and alternative biologics. Nordic producers showcase low somatic-cell averages, proving preventive systems can maintain output while shrinking antibiotic loads.
Asia-Pacific is the fastest propeller with a 5.86% CAGR thanks to surging dairy consumption in China, India, and Southeast Asia. Larger herd sizes, international joint ventures, and Western farming models necessitate structured mastitis control. Investments in milk-analysis labs and vet services unlock pent-up demand for culture kits, vaccines, and AI platforms, enlarging regional share of the bovine mastitis market. Latin America and the Middle East & Africa trail at slightly lower yet robust CAGRs of 5.72% and 5.31% respectively as integrated farm projects scale up in Brazil and the Gulf states.
List of Companies Covered in this Report:
- Bayer
- Biogénesis Bagó
- Bioveta, a.s.
- Boehringer Ingelheim
- BouMatic
- Ceva Santé Animale
- Dechra Pharmaceuticals
- Elanco
- Hipra
- ImmuCell
- Interchemie werken “De Adelaar” B.V.
- Merck
- Nimrod Veterinary Products
- Norbrook Laboratories Ltd.
- Pecus Healthcare
- Phibro Animal Health
- Vetoquinol Group
- Virbac
- Westway Health
- Zoetis
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Biogénesis Bagó
- Bioveta, a.s.
- Boehringer Ingelheim GmbH
- BouMatic
- Ceva Santé Animale
- Dechra Pharmaceuticals
- Elanco Animal Health
- HIPRA
- ImmuCell Corporation
- Interchemie werken “De Adelaar” B.V.
- Merck & Co., Inc.
- Nimrod Veterinary Products
- Norbrook Laboratories Ltd.
- Pecus Healthcare
- Phibro Animal Health Corporation
- Vetoquinol Group
- Virbac SA
- Westway Health
- Zoetis Inc.
